Taipei, Taiwan

Yueh-Hsiung Kuo

This inventor holds 22 USPTO granted patents and 9 published patent applications, primarily in Pharmaceutical Compounds. Top assignees: Joben Bio-Medical Co., Ltd., National Taiwan University, China Medical University. Active years: 2001-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yueh-Hsiung Kuo. Retrieved from https://idiyas.com/inventor/yueh-hsiung-kuo

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 22 

% Patents Active = 68.2

Average Co-Inventor Count = 3.1

ph-index = 2

Forward Citations = 19(Granted Patents)


Location History:

  • Kaohsiung, TW (2014 - 2015)
  • Taipei, TW (2001 - 2021)
  • Taichung, TW (2011 - 2021)

Company Filing History:


Years Active: 2001-2021

Loading Chart...
Areas of Expertise:
Benzofuran Lignans
Caffeic Acid Derivatives
Dehydroeburicoic Acid
Hyperlipidemia
Polysaccharide Nanocomposites
Catechol-Based Derivatives
Estrogenic Activity
Hepatitis B Treatment
22 patents (USPTO):Explore Patents

Title: Innovations and Contributions of Yueh-Hsiung Kuo in Cancer Research

Introduction: Yueh-Hsiung Kuo is a notable inventor based in Taipei, Taiwan, with an impressive portfolio of 22 patents. His work primarily focuses on the development of innovative methods and compounds for cancer treatment, showcasing significant advancements in biomedical research.

Latest Patents: Among his latest patents is the invention titled "Use of benzofuran lignans to induce IL-25 expression and suppress mammary tumor metastasis." This method involves administering an effective amount of a specific compound to a subject in need, aimed at suppressing tumor metastasis. Furthermore, this patent outlines a process for treating cancer by combining a chemotherapy agent with the aforementioned compound, leading to the creation of pharmaceutical compositions designed for both suppressing tumor metastasis and treating cancer.

Another notable patent from Kuo is related to "Caffeic acid derivatives for anti-angiogenesis." This innovation includes a series of methyl caffeate derivatives that exhibit biological activity in preventing angiogenesis. The findings suggest that these compounds inhibit angiogenesis by regulating VEGF/VEGFR-2 and its downstream signaling cascades in vascular endothelial cells.

Career Highlights: Throughout his career, Kuo has made substantial contributions to cancer research and treatment through his inventions. His expertise in pharmacology and medicinal chemistry has propelled advancements in the development of compounds aimed at combating cancer.

Collaborations: Kuo has collaborated with several professionals in his field, including Bi-Fong Lin and Chun-Ching Shih. Their joint efforts have significantly enhanced the F research output and innovation within their respective organizations.

Conclusion: Yueh-Hsiung Kuo's contributions to cancer research through his patents reflect a deep commitment to improving therapeutic options for cancer patients. His innovative inventions and collaborations will undoubtedly continue to make an impact in the field of biomedical research and drug development.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…